Late last year, the National Institutes of Health's Recombinant DNA Advisory Committee expressed a number of concerns about how Nucleonics has designed its proposed phase I trial for its expressed RNAi hepatitis B therapy, NucB 1000.

Chief among the issues raised by the RAC reviewers are the doses Nucleonics proposes to test in the clinical study, which the committee believes could potentially overwhelm patients' natural RNAi processes, and the company's decision to evaluate NucB 1000 only in mouse models in its preclinical research.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.